Thomas Shrader
Stock Analyst at BTIG
(2.84)
# 1,459
Out of 4,414 analysts
34
Total ratings
40.62%
Success rate
0.14%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $11 | $3.06 | +259.48% | 1 | Dec 21, 2023 | |
| PMN ProMIS Neurosciences | Initiates: Buy | $8 | $1.92 | +316.93% | 1 | Oct 3, 2023 | |
| DTIL Precision BioSciences | Maintains: Buy | $180 → $60 | $10.48 | +472.52% | 1 | Jul 28, 2023 | |
| BHVN Biohaven Pharmaceutical Holding Company | Reiterates: Buy | $24 | $40.18 | -40.27% | 2 | Jun 6, 2023 | |
| ANNX Annexon | Maintains: Buy | $15 → $7 | $4.75 | +47.37% | 2 | May 25, 2023 | |
| COYA Coya Therapeutics | Initiates: Buy | $15 | $8.67 | +73.01% | 1 | May 18, 2023 | |
| ATHA Athira Pharma | Maintains: Buy | $33 → $10 | $2.04 | +390.20% | 2 | Mar 30, 2023 | |
| BCAB BioAtla | Maintains: Buy | $68 → $13 | $3.37 | +285.76% | 3 | Mar 28, 2023 | |
| VRNA Verona Pharma | Maintains: Buy | $26 → $31 | $15.22 | +103.68% | 3 | Mar 20, 2023 | |
| ALEC Alector | Maintains: Buy | $54 → $16 | $5.28 | +203.03% | 1 | Mar 2, 2023 | |
| PCVX Vaxcyte | Initiates: Buy | $69 | $63.71 | +8.30% | 1 | Nov 17, 2022 | |
| GANX Gain Therapeutics | Maintains: Buy | $30 → $10 | $2.97 | +236.70% | 2 | Nov 14, 2022 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $15 → $22 | $3.25 | +576.92% | 2 | Oct 5, 2022 | |
| INMB INmune Bio | Maintains: Buy | $31 → $14 | $11.60 | +20.69% | 2 | May 24, 2022 | |
| NUVB Nuvation Bio | Initiates: Buy | n/a | $3.20 | - | 1 | Mar 8, 2021 | |
| VYGR Voyager Therapeutics | Downgrades: Neutral | n/a | $8.36 | - | 1 | Feb 3, 2021 | |
| DNLI Denali Therapeutics | Downgrades: Neutral | n/a | $16.16 | - | 1 | Oct 16, 2020 | |
| VCNX Vaccinex | Downgrades: Neutral | n/a | $6.00 | - | 1 | Sep 23, 2020 | |
| ETNB 89bio | Maintains: Buy | n/a | $8.75 | - | 1 | Sep 15, 2020 | |
| GERN Geron | Maintains: Buy | n/a | $4.08 | - | 1 | Apr 3, 2020 | |
| BIIB Biogen | Downgrades: Hold | n/a | $216.13 | - | 3 | Feb 21, 2019 | |
| WINT Windtree Therapeutics | Downgrades: Hold | n/a | $4.49 | - | 1 | Jun 30, 2017 |
Ovid Therapeutics
Dec 21, 2023
Initiates: Buy
Price Target: $11
Current: $3.06
Upside: +259.48%
ProMIS Neurosciences
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $1.92
Upside: +316.93%
Precision BioSciences
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $10.48
Upside: +472.52%
Biohaven Pharmaceutical Holding Company
Jun 6, 2023
Reiterates: Buy
Price Target: $24
Current: $40.18
Upside: -40.27%
Annexon
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $4.75
Upside: +47.37%
Coya Therapeutics
May 18, 2023
Initiates: Buy
Price Target: $15
Current: $8.67
Upside: +73.01%
Athira Pharma
Mar 30, 2023
Maintains: Buy
Price Target: $33 → $10
Current: $2.04
Upside: +390.20%
BioAtla
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $3.37
Upside: +285.76%
Verona Pharma
Mar 20, 2023
Maintains: Buy
Price Target: $26 → $31
Current: $15.22
Upside: +103.68%
Alector
Mar 2, 2023
Maintains: Buy
Price Target: $54 → $16
Current: $5.28
Upside: +203.03%
Vaxcyte
Nov 17, 2022
Initiates: Buy
Price Target: $69
Current: $63.71
Upside: +8.30%
Gain Therapeutics
Nov 14, 2022
Maintains: Buy
Price Target: $30 → $10
Current: $2.97
Upside: +236.70%
Acumen Pharmaceuticals
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $3.25
Upside: +576.92%
INmune Bio
May 24, 2022
Maintains: Buy
Price Target: $31 → $14
Current: $11.60
Upside: +20.69%
Nuvation Bio
Mar 8, 2021
Initiates: Buy
Price Target: n/a
Current: $3.20
Upside: -
Voyager Therapeutics
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $8.36
Upside: -
Denali Therapeutics
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.16
Upside: -
Vaccinex
Sep 23, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.00
Upside: -
89bio
Sep 15, 2020
Maintains: Buy
Price Target: n/a
Current: $8.75
Upside: -
Geron
Apr 3, 2020
Maintains: Buy
Price Target: n/a
Current: $4.08
Upside: -
Biogen
Feb 21, 2019
Downgrades: Hold
Price Target: n/a
Current: $216.13
Upside: -
Windtree Therapeutics
Jun 30, 2017
Downgrades: Hold
Price Target: n/a
Current: $4.49
Upside: -